Iovance Biotherapeutics, Inc. IOVA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s retained earnings?
- Iovance Biotherapeutics, Inc. (IOVA) reported retained earnings of -$2.85B in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s retained earnings changed year-over-year?
- Iovance Biotherapeutics, Inc.'s retained earnings decreased by 14.2% year-over-year, from -$2.5B to -$2.85B.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s retained earnings has grown at a 27.3% compound annual growth rate (CAGR), from -$830.19M to -$2.78B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.